Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Blueprint Medicines Corp (BPMC)

Blueprint Medicines Corp (BPMC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,572,281
  • Shares Outstanding, K 62,617
  • Annual Sales, $ 249,380 K
  • Annual Income, $ -506,980 K
  • 60-Month Beta 0.65
  • Price/Sales 26.78
  • Price/Cash Flow N/A
  • Price/Book 21.01
Trade BPMC with:

Options Overview Details

View History
  • Implied Volatility 48.70% ( -1.41%)
  • Historical Volatility 47.14%
  • IV Percentile 32%
  • IV Rank 38.98%
  • IV High 74.91% on 01/05/24
  • IV Low 31.96% on 12/07/23
  • Put/Call Vol Ratio 0.42
  • Today's Volume 518
  • Volume Avg (30-Day) 363
  • Put/Call OI Ratio 0.82
  • Today's Open Interest 28,800
  • Open Int (30-Day) 26,956

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -1.29
  • Number of Estimates 10
  • High Estimate -1.10
  • Low Estimate -1.43
  • Prior Year -2.19
  • Growth Rate Est. (year over year) +41.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
84.62 +24.04%
on 04/19/24
111.02 -5.46%
on 05/14/24
+16.58 (+18.76%)
since 04/17/24
3-Month
80.42 +30.51%
on 02/22/24
111.02 -5.46%
on 05/14/24
+14.70 (+16.29%)
since 02/16/24
52-Week
43.89 +139.14%
on 10/25/23
111.02 -5.46%
on 05/14/24
+50.50 (+92.73%)
since 05/17/23

Most Recent Stories

More News
Blueprint Medicines: Q1 Earnings Snapshot

Blueprint Medicines: Q1 Earnings Snapshot

BPMC : 104.96 (-1.58%)
Blueprint Medicines: Q4 Earnings Snapshot

Blueprint Medicines: Q4 Earnings Snapshot

BPMC : 104.96 (-1.58%)
Chart of the Day: Does Blueprint Medicines Have a Blueprint for Success?

The Chart of the Day belongs to the cancer biomedical company Blueprint Medicines (BPMC) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical...

BPMC : 104.96 (-1.58%)
Why Blueprint Medicines Stock Soared Today

The precision-treatment company saw stronger-than-expected sales in its first full quarter following the launch of Ayvakit.

BPMC : 104.96 (-1.58%)
Blueprint Medicines: Q3 Earnings Snapshot

Blueprint Medicines: Q3 Earnings Snapshot

BPMC : 104.96 (-1.58%)
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective October 1, 2023, the Compensation Committee of Blueprint...

BPMC : 104.96 (-1.58%)
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective September 1, 2023, the Compensation Committee of Blueprint...

BPMC : 104.96 (-1.58%)
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective August 1, 2023, the Compensation Committee of Blueprint...

BPMC : 104.96 (-1.58%)
Why Shares of Blueprint Medicines Are Falling Wednesday

The company had generally improved earnings.

BPMC : 104.96 (-1.58%)
Blueprint Medicines: Q2 Earnings Snapshot

Blueprint Medicines: Q2 Earnings Snapshot

BPMC : 104.96 (-1.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Blueprint Medicines Corporation is a biopharmaceutical company focused on developing the potentially transformational precision medicines to address patients with genomically defined cancers and rare diseases.

See More

Key Turning Points

3rd Resistance Point 110.95
2nd Resistance Point 109.06
1st Resistance Point 107.01
Last Price 104.96
1st Support Level 103.07
2nd Support Level 101.18
3rd Support Level 99.13

See More

52-Week High 111.02
Last Price 104.96
Fibonacci 61.8% 85.38
Fibonacci 50% 77.46
Fibonacci 38.2% 69.53
52-Week Low 43.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar